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STUDY PROTOCOL
The Danish comorbidity in liver transplant 
recipients study (DACOLT): a non-interventional 
prospective observational cohort study
Magda Teresa Thomsen1†, Julie Høgh1†, Andreas Dehlbæk Knudsen1, Anne Marie Reimer Jensen1, 
Marco Gelpi1, Gerda E. Villadsen2, Rozeta Abazi3, Peter Holland‑Fischer4, Lars Køber5, Otto Clemmesen6, 
Paul Suno Krohn7, Jens Hillingsø7, Tina Vilsbøll8, Tor Biering‑Sørensen9, Klaus Fuglsang Kofoed4, 
Børge Grønne Nordestgaard10, Allan Rasmussen7 and Susanne Dam Nielsen1*  
Abstract 
Background: Liver transplantation is the only curative treatment for patients with end‑stage liver disease. Short‑
term survival has improved due to improved surgical techniques and greater efficacy of immunosuppressive drugs. 
However, long‑term survival has not improved to the same extent as the short‑term survival, and the 10‑year survival 
after liver transplantation is 60%. In addition to liver‑ and transplant‑related causes, comorbidities such as cardiovas‑
cular, pulmonary, renal, and metabolic diseases have emerged as leading causes of morbidity and mortality in liver 
transplant recipients. The objective of this study is to assess the burden of comorbidities and identify both liver‑ and 
transplant‑related risk factors as well as traditional risk factors that contribute to the pathogenesis of comorbidity in 
liver transplant recipients.
Methods/design: The Danish Comorbidity in Liver Transplant Recipients (DACOLT) study is an observational, longi‑
tudinal study. We aim to include all adult liver transplant recipients in Denmark (n = approx. 600). Participants will be 
matched by sex and age to controls from the Copenhagen General Population Study (CGPS) and the Copenhagen 
City Heart Study (CCHS). Physical and biological measures including blood pressure, ankle–brachial index, spirometry, 
exhaled nitric oxide, electrocardiogram, transthoracic echocardiography, computed tomography (CT) angiography 
of the heart, unenhanced CT of chest and abdomen and blood samples will be collected using uniform protocols in 
participants in DACOLT, CGPS, and CCHS. Blood samples will be collected and stored in a research biobank. Follow‑up 
examinations at regular intervals up to 10 years of follow‑up are planned.
Discussion: There is no international consensus standard for optimal clinical care or monitoring of liver transplant 
recipients. This study will determine prevalence, incidence and risk factors for comorbidity in liver transplant recipients 
and may be used to provide evidence for guidelines on management, treatment and screening and thereby contrib‑
ute to improvement of the long‑term survival.
Trial registration ClinicalTrials.gov: NCT04777032; date of registration: March 02, 2021.
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
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Background
Liver transplantation is the only curative treatment for 
patients with end-stage liver disease. Improved surgical 
techniques and greater efficacy of immunosuppressive 
drugs to prevent rejection have improved the short-
term survival of liver transplant recipients. According 
to the European Liver Transplant Registry the current 
1-year survival rate in liver transplant recipients is 86% 
[1]. However, long-term survival has not improved to 
the same extent with 5- and 10-year survival rates of 
74% and 60%, respectively [1], and efforts to improve 
the long-term survival are needed.
In addition to liver- and transplant related causes, 
cardiovascular, pulmonary, kidney, and metabolic dis-
eases contribute to the increased morbidity and mor-
tality in liver transplant recipients [2–4]. Further 
knowledge of prevalence, incidence and risk factors for 
development of comorbidity is needed to identify high-
risk individuals, to develop to targeted interventions, 
and to improve survival.
Cardiovascular diseases (CVD) have emerged as a 
leading cause of morbidity and mortality in liver trans-
plant recipients [5–7], but the magnitude is not well 
explored, and a systematic review described a highly 
variable incidence of 1–41% for CVD [8]. Few stud-
ies have included controls, but one study indicated a 
higher incidence of ECG abnormalities in liver trans-
plant patients than in the background population [9]. 
However, whether liver transplantation is an independ-
ent risk factor for CVD is poorly elucidated, and large, 
prospective cohort studies are needed to provide fur-
ther insight into the risk factors and mechanisms driv-
ing CVD in liver transplant recipients.
Pulmonary and respiratory diseases, including pul-
monary hypertension and hepatopulmonary syndrome 
are frequently seen in liver transplant candidates prior 
to transplantation [10]. In the acute post-operative 
phase after liver transplantation, pulmonary complica-
tions are frequent and both infectious and non-infec-
tious pulmonary diseases contribute to morbidity and 
mortality in the acute phase [11]. The extent to which 
pulmonary diseases contribute to morbidity beyond 
the acute phase and the impact on long-term survival 
is unknown.
Studies have shown that mortality related to renal 
diseases increases over time post-transplantation [2]. 
Thus, renal insufficiency may be an important risk fac-
tor for late post-transplant mortality in liver transplant 
recipients. The aetiology leading to post-transplant 
renal failure is multifactorial and include use of immu-
nosuppressive medication, metabolic syndrome, dia-
betes, circulating immunocomplexes, and factors that 
contribute to hepatorenal syndrome [12]. Despite the 
use of renal-sparing immunosuppression protocols, 
renal insufficiency remains a concern [2].
Metabolic syndrome, obesity and diabetes are highly 
prevalent in liver transplant recipients [13]. In addition, 
the use of certain immunosuppressive medication may 
induce dyslipidaemia [14]. Non-alcoholic fatty liver dis-
ease (NAFLD) is a common liver disease and is consid-
ered the liver manifestation of the metabolic syndrome 
[15]. Patients with NAFLD have an increased risk of car-
diovascular diseases, kidney diseases and liver fibrosis 
[16, 17]. Although these are common comorbidities with 
potential impact on quality of life, morbidity and mortal-
ity, there is limited knowledge about metabolic diseases 
in liver transplant recipients, and studies to determine 
the incidence and whether liver transplantation is an 
independent risk factor for metabolic syndrome are 
needed.
Study objectives
The overall objective of this study is to determine the 
burden of comorbidities in liver transplant recipients 
and to examine whether this differs from the background 
population. Furthermore, we want to identify both liver- 
and transplant-related risk factors as well as traditional 
risk factors that contribute to the pathogenesis of comor-
bidity in liver transplant recipients.
AIM 1: To determine the prevalence and incidence of 
cardiovascular, respiratory, renal and metabolic dis-
eases in liver transplant recipients, and whether the 
prevalence and incidence of these comorbidities are 
different from that of the background population.
AIM 2: To identify liver- and transplant-related risk 
factors and traditional risk factors that contribute to 
the pathogenesis of cardiovascular, respiratory, renal 
and metabolic diseases in liver transplanted recipi-
ents and study potential interactions between these.
AIM 3: To describe the kinetics of cytokines, 
chemokines, immune cells, proteomics and metabo-
lomics after liver transplantation and identify bio-
markers that can identify liver transplant recipients 
at high risk of developing cardiovascular, respiratory, 
renal, and metabolic diseases.
Keywords: Liver transplantation, Comorbidity, Cardiovascular diseases, Respiratory diseases, Metabolic diseases, 
Renal diseases
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Methods/design
The DACOLT study is a non-interventional, observa-
tional, longitudinal study to be initiated in March 2021. 
The study aims to include all liver transplant recipi-
ents living in Denmark (n = 580) as well as all patients 
who will be liver transplanted from 01.03.2021 until 
01.03.2033 (estimated n = 600). Controls will be included 
from the Copenhagen General Population Study (CGPS) 
and the Copenhagen City Heart Study (CCHS).
Liver transplant recipients and controls will have uni-
formly measured clinical data and information regard-
ing risk factors. Clinically measured primary outcomes 
include (1) coronary CT angiography, cardiac structure 
and function determined by echocardiography and car-
diac CT, and electrophysiological abnormalities deter-
mined by electrocardiogram (ECG), (2) dynamic lung 
function indices measured by spirometry, (3) estimated 
glomerular filtration rates, (4) diabetes and dyslipidae-
mia. Several other outcomes are measured. Table 1 pro-
vides a complete overview of all clinical and physical 
measurements, Table  2 of biochemical measures, and 
Table 3 an overview of the content of the questionnaires 
used in the study.
Follow‑up examinations
The participants in the DACOLT study will be examined 
at inclusion and after 10  years with extensive question-
naires, eNO test, computed tomography (CT) scans and 
transthoracic echocardiography (TTE) as well as physical 
measurements, ECG, spirometry and blood samples. Fur-
thermore, every second year, participants will be invited 
to participate in a less extensive examination including 
Table 1 Clinical measurements and collection of biomaterials
CACS coronary artery calcium score, CT computed tomography, MSCT multi-slice computed tomography, PBMC peripheral blood mononuclear cell
Measurements Description
Anthropometry Height: Stadiometer without shoes
Weight: Scale (Soehnle, Nassau, Germany) without shoes or heavy clothing
Waist and hip circumference: Measuring tape (SECA, Birmingham, UK)
Ankle–brachial‑index Doppler (Sonotrax Basic A, Edan, San Diego, CA, U.S.)
Blood pressure IntelliVue MP5SC (Philips, Amsterdam, Netherlands)
Electrocardiogram Cardiosoft V6.73 (GE Healthcare, Buckinghamshire, UK)
Spirometry EasyOne® ultrasonic spirometer (ndd Medical, Zürich, Switzerland)
eNO NIOX VERO® (Aerocrine AB, Solna, Sweden)
CT scans CT angiography, CACS, CT chest, CT upper abdomen. 320‑detector MSCT 
(Canon Aquilion ONE, PRISM, Canon Medical Systems, Otawara, Japan)
Transthoracic echocardiography Vivid 9 Ultrasound System (GE Healthcare, Horten Norway) M‑mode, 
colour tissue doppler, conventional spectral doppler, 2D speckle tracking, 
3‑dimensional echocardiography
Biobank PBMC, plasma, serum
Table 2 Hematological and biochemical measurements
Measurements Description
Hematology Hemoglobin, hematocrit, leucocytes, differential count, thrombocytes, red cell dimensions, complement C3
Electrolytes and iron 
metabolism
Sodium, potassium, calcium, iron, magnesium, ferritin, transferrin, chloride
Liver/ organ related Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, bilirubin, gamma glutamyltransferase, albumin, 
antitrypsin, amylase, creatinine kinase, lactate dehydrogenase
Coagulation Activated partial thromboplastin time, coagulation factor II + VII + X, D‑dimer, fibrinogen
Lipids Total cholesterol, remnant cholesterol, HDL cholesterol, LDL‑cholesterol, triglycerides, adiponectin, lipoprotein, apolipoprotein A, 
B, and E
Metabolic Non‑fasting glucose, fasting‑glucose, non‑fasting insulin, pro‑insulin, C‑peptide, fasting‑insulin, HbA1c, ethanol, hydrogen 
carbonate
Renal function Creatinine, urea, uric acid, eGFR
Thyroid function Thyroid stimulating hormone, free T3/T4
Immunology Immunoglobulin A and E, rheumatoid factor IgM
Inflammation High sensitivity C‑reactive protein, immunoglobulin A and B, rheumatoid factor (IgM)
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physical measurements, TTE, ECG, spirometry, blood 
samples and a smaller questionnaire (Fig. 1).
Participants
DACOLT participants and eligibility criteria
All liver transplant recipient in Denmark aged 
18–100  years will be eligible for inclusion in the 
DACOLT study. Inclusion requires the individual to be 
able to understand the study information in either Danish 
or English and to be able to provide an informed consent. 
Contraindications to the various measures performed in 
the study (i.e., renal impairment and contraindications 
to a contrast enhanced CT) do not exclude participants 
from other parts of the study.
Controls from the Copenhagen General Population Study 
and the Copenhagen City Heart Study
CGPS is an ongoing observational population study with 
more than 110,000 participants from the greater Copen-
hagen area. All residents in the greater Copenhagen 
area > 40 years and 25% of 20–40 years old are invited to 
participate in the study and in follow-up examinations 
every decade. A random sample of 10,000 participants 
aged ≥ 40 years had a contrast enhanced CT of the chest 
including CT angiography of the heart performed. Of 
these, 6500 had a contrast enhanced CT of the abdomen.
CCHS includes a random population sample included 
from the greater Copenhagen area. Health surveys have 
been repeated 5 times between 1976 and 2015. Almost 
4500 participants were randomly selected for echocardi-
ography in 2013–2015.
Physical and clinical measurements
All data are collected using uniform protocols in the 
CGPS, CCHS and the DACOLT study (Fig. 1). A physical 
exam including anthropometrics, pulse, peripheral arte-
rial saturation is performed by trained clinical staff.
Blood pressure and ankle–brachial index
Blood pressure is measured electronically on both the 
right and left arm with the participant in a relaxed seated 
position using IntelliVue MP5SC (Philips, Amsterdam, 
Netherlands). Ankle–brachial-index (ABI) is measured 
in a supine position in both extremities using a Doppler 
meter (Sonotrax Basic A 294534, Edan, San Diego, CA, 
US) by determining the systolic pressure of the posterior 
tibial artery or alternately the pressure of dorsalis pedis 
artery.
ECG
ECG is measured using a 12-lead ECG (Cardiosoft V6.73 
GE Healthcare, Buckinghamshire, UK). The ECGs are 
stored electronically.
Table 3 Overview and examples of variables recording for questionnaires
COPD chronic obstructive pulmonary disease
Variable Examples
Large questionnaire regarding lifestyle and health
 Smoking Current, previous and passive smoking. Cumulative pack‑years, type, filters, e‑cigarettes
 Alcohol and drug use Current and previous alcohol intake, intravenous drug use, cannabis
 Environmental exposure Occupational dusts, organic‑ and inorganic gasses, vapors, fumes
 Demographics Ethnicity, nationality, marital status, children
 Socioeconomic status Level of education, household income
 Work Employment, income, night‑work
 Diet Meat intake, vegetable intake
 Daily living Physical activity, social support, sleeping, stress, sun exposure
 Medication use Prescription and doses
 Gender, ethnicity Ethnicity, place of birth
 Perinatal/childhood events Birthweight, delivery at term, breast feeding, respiratory tract infections
 Family history of diseases Acute myocardial infarction, stroke, asthma, COPD, hypertension, diabetes, cancer, depression
 Questions for females Pregnancies, menarche‑ and menopause age, abortions
 Self‑reported disease Asthma, COPD, allergies, diabetes
 Symptoms Angina, dyspnea, cough, wheeze, sputum, reflux
Fracture Risk Assessment Tool (FRAX®)
 Risk factors for fractures Previous fracture, parent fractured hip, glucocorticoid use, rheumatoid arthritis
Major Depression Inventory (MDI)
 Self‑report mood questionnaire Lack of energy, feeling restless, appetite changes, feeling less self‑confident
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Spirometry and nitric oxide in exhaled breath
Forced expiratory volume in the first second (FEV1) and 
forced vital capacity (FVC) are measured by spirom-
etry using an EasyOne World Spirometer (ndd Medical, 
Zurich, Switzerland) with one-use spirettes (ndd Medi-
cal). Spirometry is performed in accordance with Ameri-
can Thoracic Society/European Respiratory guidelines 
[18]. In participants where the  FEV1/FVC < 0.7 a repeat 
spirometry is performed 15  min after bronchodilation 
with inhalation of 400  µg salbutamol (Ventoline Dis-
kus, Glaxo Smoth Kline, Middlesex, UK). Nitric oxide in 
exhaled breath (eNO) is measured using NIOX VERO 
(Aerocrine AB, Solna, Sweden).
Collection of biomaterials
At time of inclusion blood samples will be collected for 
routine biochemical analyses (Table 2). A total of 84 ml 
blood will be collected for a research biobank, and 
peripheral blood mononuclear cells (PBMC), serum 
and plasma will be stored for analyses of inflamma-
tion markers (chemokines, cytokines, soluble surface 
markers), coagulation markers (standard and functional 
platelet aggregation test), simulation assays and flow-
cytometry of PBMC, endothelial function markers 
(asymmetric dimethylarginine (ADMA), syndecan-1, 
thrombomodulin and sE-selectin), markers of microbial 
translocation and bacterial degradation (sCD14, lipopol-
ysaccharide, trimethylamine N-oxide), markers of lung 
tissue (alpha-1-antitrypsine, endothelin-1), liver markers 
(hyaluronic acid and fibrosis markers) and metabolomics 
and multiomics.
At all follow-up visits, routine blood samples will be 
drawn and analysed.
Questionnaires
All participants in DACOLT will complete an exten-
sive questionnaire regarding lifestyle, health, respiratory 
symptoms and medication, identical to the questionnaire 
developed and used in the CGPS and CCHS (Table  3). 
Data based on this questionnaire has been published 
on several occasions [19–23]. Furthermore, DACOLT 
participants will also complete a separate question-
naire regarding depression symptoms based on Major 
Depression Inventory [24] (International Classification 
of Diseases (ICD)-10) and complete the Fracture Risk 
Assessment Tool (FRAX®) [25] which is an online algo-
rithm with 12 questions to assess the risk of hip fracture. 
All these questionnaires will be completed at time of 
Baseline Every 2 years 10-years follow-up






Weight, height, waist and hip 
circumference, saturaon, blood 
pressure
Electrocardiogram
Lung funcon and eNO
Imaging





Haematology, electrolytes, iron 
metabolism, liver funcon, 
coagulaon, lipids, metabolic status, 
renal funcon, thyroid funcon, 
immunologic status, inflammatory 
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Insulin, glucose and lipids.
Biobank
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Fig. 1 Overview of data collection in the DACOLT study, the Copenhagen General Population Study (CGPS) and the Copenhagen City Heart Study 
(CCHS). CT computed tomography, FRAX® Fracture Risk Assessment Tool
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inclusion and at the 10  year follow up. A less extensive 
questionnaire will be completed at 2-, 4-, 6- and 8-year 
follow-up.
CT scans
CT scans will be performed with a 320-detector MSCT 
(Canon Aquilion ONE, PRISM, Canon Medical Sys-
tems, Otawara, Japan) at Rigshospitalet, University of 
Copenhagen, using identical protocols for DACOLT and 
GCPS participants. First, in backrest and while holding 
the inspiration, a high-resolution CT will be performed 
including all lung parenchyma. Afterwards, CT scan 
of the heart, liver and abdominal fat will be performed. 
At last, an intravenous contrast agent (Visipaque 78 ml, 
320 mg/ml) will be infused with a flowrate of 5 ml/s fol-
lowed by a saline chaser and contrast enhanced thoracic 
and abdominal CT angiography will be performed. The 
complete CT scan protocol includes several scans per-
formed in the following sequence: Unenhanced CACS, 
scan of the upper abdomen, abdominal single slice 
acquisition for measurements of visceral adipose tissue, 
low-dose chest CT and a contrast enhanced coronary 
angiography with iodixanol (Visipaque®, GE Health-
care, Brøndby, Denmark). Oral β1-antagonist (Metocar, 
STADA Nordic, Herlev, Denmark) will be administered 
to patients with a heart rate > 60 bpm and systolic blood 
pressure > 110  mmHg unless contraindicated. Partici-
pants with moderate to severe COPD/asthma will receive 
Ivabradin 15 mg (Procoralan, Servier, Fredriksberg, Den-
mark) instead of a β1-antagonist. Immediately before CT 
angiography is performed, one dose of 0.4 mg oral spray 
nitroglycerin (Nitrolingual, Pohl Boskamp, Hohenlock-
stedt, Germany) is administered unless contraindicated. 
The maximum allowed radiation dose for the com-
plete sequence is 8  mSv, and CT will not be performed 
in patients where the expected radiation dose exceeds 
8 mSv.
Transthoracic echocardiography
Echocardiography will be performed using a pre-
specified comprehensive protocol using the Vivid 9 
Ultrasound System (GE Healthcare, Horten, Norway). 
Participants will be examined in the left lateral decubi-
tus position with conventional echocardiography; includ-
ing M-mode, and colour tissue doppler (TDI), 2D speckle 
tracking for deformation analyses (strain) as well as 
3-dimensional echocardiography. Echocardiograms will 
be stored in a GE Healthcare image vault, and images will 
be analysed offline with commercially available post-pro-
cessing software.
Other data sources
For DACOLT participants, liver- and transplantation-
related variables will be retrieved from patient records. 
In Denmark, all liver transplant recipients are rou-
tinely examined annually with liver biopsies, magnetic 
resonance imaging (MRI), including MR elastography, 
and routine blood samples. Furthermore, information 
on vital status, medicine use and discharge diagnosis 
can be retrieved from National Danish registries. The 
Civil Registration System (CRS) contains information 
on vital status, date of emigration and death of every 
resident in Denmark [26]. The Danish National Patient 
Register (NPR) contains information on all hospital 
admissions to Danish hospitals including discharge 
diagnoses according to the ICD-10 from 1994 [27]. 
From the NPR, data on admissions due to cardiovas-
cular, lung, bone, metabolic, and liver diseases will be 
retrieved. Information regarding purchase and use of 
medication related to these diseases will be retrieved 
from the registry of Medicinal Product Statistics that 
contains information on medicine since 1994, including 
all prescription and non-prescription drug sales from 
pharmacies, and all deliveries from general practition-
ers and hospitals [28].
Sample size
The current study includes several endpoints, and the 
necessary sample size varies accordingly.
Previous data from the CGPS have shown coronary 
atherosclerosis in 50% of the background population [29]. 
In the following we assume that 90% of the invited liver 
transplant recipients are included in the study.
Assuming coronary atherosclerosis in 50% of the CGPS 
participants [29], an alpha of 5%, 540 liver transplant 
recipients and 5400 controls, we will, with a power (1-β) 
of 0.90, be able to show a prevalence ratio of 1.15 for ath-
erosclerosis. Assuming ECG changes in 11% of CGPS 
participants [30], an alpha of 5%, 540 liver transplant 
recipients and 5,400 controls, we will with a power (1-β) 
of 0.82 be able to show a prevalence ratio of 1.4 to have 
ECG abnormalities. In the Danish general population, 1 
unit (%) decrease in absolute global longitudinal strain 
(GLS) is associated with 10% increased risk of heart dis-
ease [31]. Assuming an alpha of 1%, a standard deviation 
of 3.5%, 540 liver transplant recipients and 2,160 con-
trols, we will be able to show a difference of 1% GLS with 
a power (1-β) of 0.99.
Planned statistical analyses
Descriptive statistical analyses will be used to assess 
demographics, risk factors, and physical measurements. 
Groups will be compared using t-test or Mann–Whitney 
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U test for continuous data and χ2 tests or Fisher’s test 
for categorical data. The large cohort of controls permits 
each liver transplant recipients to be matched on age and 
sex with between 5 and 20 controls. In cross-sectional 
studies the prevalence of the respective diseases among 
liver transplant recipients will be compared to the preva-
lence among the control group using logistic regression 
adjusted for traditional and/or presumed risk factors. 
Likewise, numeric variables will be compared using lin-
ear regression adjusted for traditional and/or presumed 
risk factors. For prospective studies, Cox regression, 
Kaplan–Meier curves, log-rank test, and mixed effect 
models will be used. In general, missing data is expected 
to be low and multiple imputations are not likely to be 
required. Characteristics for loss to follow-up will be 
assessed.
Ethical considerations
All participants provide oral and written informed 
consent before study inclusion. The DACOLT study 
(H-20052199), CGPS (H-KF-01-144/01) and CCHS 
(HEH-2015-045) have obtained approval from the Ethics 
Committee of the Capital Region, Denmark.
CT scans expose participants to a radiation dose of 
maximum eight millisieverts (mSv). Although low, this 
radiation dose may cause an increase in lifetime risk of 
radiation induced cancer. Before giving consent to the 
CT scan, participants have received both written and 
oral information about the radiation dose and cancer 
risk. The CT scans will be reviewed and described by a 
radiologist. The participants will, if they provide consent, 
receive information if there are signs of clinically signifi-
cant disease. Participants will give a specific consent to 
the storage of biological samples in a research biobank. 
All adverse events will be recorded.
Discussion
The 10-year survival after liver transplantation is 60%. In 
addition to liver- and transplant-related causes, comor-
bidities such as cardiovascular, pulmonary, renal, and 
metabolic diseases are leading causes of morbidity and 
mortality in liver transplant recipients. The primary goal 
of this study is to identify the burden and risk factors of 
post-transplant comorbidities and thereby contribute 
to knowledge of comorbidities, in order to target inter-
ventions and to help improve long-term survival. The 
primary outcome measures are defined within the differ-
ent disease categories i.e., cardiovascular-, respiratory-, 
renal- and metabolic comorbidities. Furthermore, the 
study will establish a research biobank for studies assess-
ing the pathogenesis of comorbidities in liver transplant 
recipients.
The burden of comorbidity in liver transplant recipi-
ents is not well described, and to our best knowledge 
there is no international consensus standard for optimal 
clinical care, screening programs or monitoring of liver 
transplant recipients [32–34].
This study was designed to assess post-transplant 
comorbidities in liver transplant recipients. Accordingly, 
the main strengths are the multimodal assessment of risk 
factors associated with post-transplantation comorbidi-
ties and the use of a large control cohort with uniform 
data collection. Additionally, the use of Danish registry 
data will allow linkage between data from the DACOLT 
cohort and cause and date of death, hospital discharge 
and prescription medicine.
There are also limitations to this study. Limitations 
include selection bias such as healthy volunteer bias, as 
liver transplant recipients with more severe illness or dis-
ability might be less likely to participate. Furthermore, 
there might be a geographical selection bias, as some of 
the inclusion (CT scan) takes place in the capital Copen-
hagen, which may result in people living outside Copen-
hagen being less likely to participate in this part of the 
study. Controls from the CGPS and CCHS are included 
at random, whereas DACOLT participants are included 
from the outpatient clinics when they are there for rou-
tine controls. Exact reason for non-participation will not 
be recorded, but the number of non-participations will be 
registered. Since the study is a prospective cohort study 
there might also be selection bias in participants lost to 
follow up. As the study collects information on early life 
events through self-reported questionnaires, there may 
be some risk of recall bias, albeit this risk is also present 
for the control groups.
In conclusion, despite improvements of the short-term 
survival after liver transplant recipients, the long-term 
survival remains poor, and efforts to improve the long-
term survival are needed. This study has the potential 
to determine prevalence, incidence and risk factors for 
development of comorbidity in liver transplant recipi-
ents and may be used to develop guidelines on screening, 
monitoring and long-term treatment of liver transplant 
recipients and thereby improve survival. Use of data will 
be confined to the study group, but potential collabora-
tors or request for data can be submitted to dacolt.rig-
shospitalet@regionh.dk.
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